The lack of a single-use system that functions equally well for microbial and mammalian processes, limited oxygen transfer in wave motion bioreactors, and difficulty in scaling up without sacrificing culture performance are all typical problems faced during bioprocessing. These issues are directly addressed by Bionet's Cell-tainer®. Its revolutionary patented 2D rocking technique that redefines what a rocking bioreactor can accomplish by providing

improved oxygen transfer rate, consistent mixing, and unparalleled kLa.The majority of traditional rocking bioreactors use a single-axis (1D) rocking motion that produces a wave-like flow inside the cultivation bag. Although this works well for mammalian cell cultures, it has trouble maintaining homogeneity and adequate oxygen transfer rates (kLa) when scaling up or working with microbial cultures. The Cell-tainer® uses a revolutionary 2D rocking mechanism in which motion happens along wo distinct axes. Owing to this unique infinity like movement in the culture medium, it

improves performance by providing very high kLa i.e. upto 400 per hr. • Minimising gradients in pH, dissolved oxygen, and nutrition levels to ensure thorough mixing.

• Providing consistent results across small and large scale.
• Advantages of the Cell-tainer®
• High oxygen transfer rates (kLa) make it ideal for both mammalian cells and microbial cultures, making it unique among single-use rocking systems.
• Suitable for growing high-density cultures, including E. coli, Pichia pastoris and also for mammalian cells.
• Pre-gamma sterilized single use bags require no cleaning or validation (SIP and CIP), minimising turnaround time.
• Scalability: Seamlessly linear scale from 150mL to 170 L. Within the same bag scale up from 250mL to 12/15L, minimizing process steps by eliminating the need for a shaker incubator stage.
• Process flexibility: Suitable for biopharma, vaccines, biosimilars, and cell therapy.
• The Cell-tainer®'s adaptability allows for smooth integration into various workflows,

including upstream biopharmaceutical production of monoclonal antibodies, recombinant

proteins, and vaccines.